Novo nordisk a/s: semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the flow trial

BagsvÆrd, denmark, 5 march 2024 – novo nordisk today announced the headline results from the kidney outcomes trial flow. the announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 october 2023, based on a recommendation from an independent data monitoring committee. the double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (ckd). the trial enrolled 3,533 people with type 2 diabetes and ckd.
NVO Ratings Summary
NVO Quant Ranking